Such data offers new perspectives on the molecular mechanisms underlying ZNF217's oncogenic functions, paving the way for developing targeted small-molecule inhibitors to suppress the ZNF217 signaling for the treatment of ZNF217-overexpressing cancers, such as high-risk B-ALL. This evidence concerns the gene ZNF217 and acute lymphoblastic leukemia.